Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock(Medical College of Wisconsin), Ravi Salgia(City Of Hope National Medical Center), David G. Pfister(Memorial Sloan Kettering Cancer Center), David S. Hong(The University of Texas MD Anderson Cancer Center), Arlene A. Forastiere(Greater Baltimore Medical Center), John Frye(Johns Hopkins University), Ranee Mehra(University of Maryland, Baltimore), Robert F. Gagel(The University of Texas MD Anderson Cancer Center), Chaan S. Ng(Johns Hopkins University), Douglas W. Ball(Johns Hopkins University), Thomas Müller(Johns Hopkins University), Mark J. Ratain(University of Chicago), Linda Janisch(Johns Hopkins University), Steven I. Sherman(The University of Texas MD Anderson Cancer Center), Lei Ye(Johns Hopkins University), Ezra E.W. Cohen(Moores Cancer Center), Roger B. Cohen(University of Pennsylvania), Forlisa Nauling(Johns Hopkins University)
Cited by 551
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2004|3.2k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k